Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

Bayer’s BlueRock Therapeutics outfit announced Jan. 13 in tandem with the annual J.P. Morgan Healthcare Conference. The phase 3 trial, dubbed exPDite-2, is expected to enroll 102 people with ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

San Diego, California Friday, January 10, 2025, 10:00 Hrs [IST] ...

Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...